Biographical Sketch
Eric A. Klein, MD, is the Head of the Section of Urologic Oncology in the Urological Institute and a staff member in the Cancer Center at Cleveland Clinic. His clinical interests are all aspects of urologic oncology, including cancers of the prostate, bladder, testis and kidney, and including all major reconstructive procedures such as continent urinary diversion. For several years, including the current edition, Dr. Klein is listed in Best Doctors in America.
Board-certified in urology, Dr. Klein is a frequent lecturer and visiting professor at numerous national and international universities. He is currently the National Medical Study Coordinator for the National Cancer Institute sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein is the editor of Urology and has been the recipient of numerous awards from the American Cancer Society, the University of Pittsburgh School of Medicine, and the Cleveland Clinic Foundation.
Dr. Klein received his medical degree from University of Pittsburgh School of Medicine in Pennsylvania. He completed his residency in urology at Cleveland Clinic and a fellowship in urology at the Memorial Sloan Kettering Cancer Center in New York.
Specialty Interests
nerve-sparing radical prostatectomy, Prostate Cancer, renal and bladder cancer, retroperitoneal lymphadenectomy, testis cancer, Bladder Cancer, Renal cancer
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate
with the pharmaceutical or medical device industries
to help develop medical breakthroughs or provide
medical education about recent trends. The
collaborations are reviewed as part of the Cleveland
Clinic’s procedures. The Cleveland Clinic publicly
discloses payments to its physicians and scientists
for speaking and consulting of
$5,000 or more per year, and any equity, royalties,
and fiduciary relationships in companies with which
they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its
doctors’ connections with industry and those of their
immediate family members. As of 8/1/2008, Dr.
Klein has reported the financial relationships
with the companies listed below. Patients should feel
free to contact their doctor about any of the
relationships and how the relationships are overseen
by the Cleveland Clinic. To learn more about the
Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to
our Integrity in Innovation page.
Consulting. Dr. Klein receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
Genomic Health, Inc.
Imalux
